32236 Safety of ixekizumab in adult patients with moderate-to-severe psoriasis: Data from 15 clinical trials with over 18,000 patient-years of exposure — Christopher Em Griffiths (2022) | RDL Network
32236 Safety of ixekizumab in adult patients with moderate-to-severe psoriasis: Data from 15 clinical trials with over 18,000 patient-years of exposure
April W. Armstrong, C. Paul, L. Puig, Wolf‐Henning Boehncke, Michael L. Freeman, Hideshi Torii, Kim Papp, Christopher Em Griffiths, Andrew Blauvelt, Kristian Reich, Melinda Gooderham, Tadashi Terui, L. Renda, Noah Agada, Wen Xu, Gaia Gallo, Mark Lebwohl
Craig L. Leonardi, Kristian Reich, Peter Foley, Hideshi Torii, Sascha Gerdes, Lyn Guenther, Melinda Gooderham, Laura K. Ferris, Christopher Em Griffiths, Hany Elmaraghy, Heidi M. Crane, Himanshu J. Patel, Russel Burge, Gaia Gallo, David Shrom, Ann N. Leung, Chen‐Yen Lin, Kim Papp
Kim Papp, Christopher Em Griffiths, Kenneth B. Gordon, Mark Lebwohl, Philippe Szapary, Yasmine Wasfi, Daphne Chan, M.-C. Hsu, Vincent Ho, Pierre‐Dominique Ghislain, Bruce Strober, Kristian Reich
Discussion(0)
No comments yet. Be the first to comment.